AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32061969 — intervention group
Group type: EXPERIMENTAL
Intervention: AFL intervention
Number of subjects: 160
Study 32061969 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 160
Study 35636031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 86
Study 32220766 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-party norm violations
Number of subjects: 0
Study 32220766 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-party norm violations
Number of subjects: 0
Study 32220766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both second- and third-party violations
Number of subjects: 0
Study 36357559 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (NMB)
Number of subjects: 128
Study 36357559 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (NMB)
Number of subjects: 128
Study 33149205 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg/day for three consecutive days
Number of subjects: 1669
Study 33149205 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1669
Study 36002314 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse drug reactions (ADRs)
Number of subjects: 100
Study 36002314 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs involved in ADRs
Number of subjects: 100
Study 36002314 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventability of ADRs
Number of subjects: 100
Study 36002314 — intervention group
Group type: EXPERIMENTAL
Intervention: Situations of noncompliance
Number of subjects: 100
Study 32334060 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate primary end point reporting
Number of subjects: 134
Study 32334060 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed definition of primary end points
Number of subjects: 134
Study 32334060 — intervention group
Group type: EXPERIMENTAL
Intervention: Undefined timing of primary end points
Number of subjects: 134
Study 32334060 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancies between registration and publication
Number of subjects: 134
Study 32334060 — intervention group
Group type: EXPERIMENTAL
Intervention: Inability to valuate prespecification of primary end points
Number of subjects: 134
Study 32334060 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter studies and sponsor‐initiated trials
Number of subjects: 134
Study 32486104 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib combined with individualized exercise programs
Number of subjects: 92
Study 32486104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Etoricoxib + exercise)
Number of subjects: 92
Study 32486104 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib
Number of subjects: 92
Study 36361100 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with six sets of 20 repetitions maximum (RM)
Number of subjects: 19
Study 36361100 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 19
Study 32544283 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted ventral mesh rectopexy (RVMR)
Number of subjects: 30
Study 32544283 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 30
Study 35609642 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation
Number of subjects: 180
Study 35609642 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension
Number of subjects: 180
Study 35609642 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work within 6 weeks
Number of subjects: 180
Study 35609642 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work within 2 weeks
Number of subjects: 180
Study 35609642 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients working before surgery
Number of subjects: 180
Study 35609642 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients returning to work
Number of subjects: 180
Study 33051719 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid infiltrated tumescent solution (0.1%)
Number of subjects: 33
Study 33051719 — intervention group
Group type: COMPARATOR
Intervention: Control tumescent solution (saline, bupivacaine lignocaine and adrenalin without tranexamic acid)
Number of subjects: 33
Study 35303025 — intervention group
Group type: EXPERIMENTAL
Intervention: Shame
Number of subjects: 110
Study 35303025 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilt
Number of subjects: 110
Study 35303025 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilt and Alcohol Use
Number of subjects: 110
Study 35303025 — intervention group
Group type: EXPERIMENTAL
Intervention: Other Drug Use
Number of subjects: 110
Study 33974020 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT (stepped-care group) for 16 weeks
Number of subjects: 152
Study 33974020 — intervention group
Group type: COMPARATOR
Intervention: In-person CBT (control group) for 16 weeks
Number of subjects: 152
Study 32306792 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐986166 (0.25 mg)
Number of subjects: 102
Study 32306792 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐986166 (0.75 mg)
Number of subjects: 102
Study 32306792 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐986166 (1.5 mg)
Number of subjects: 102
Study 32306792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 34933842 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of full-spectrum hyaluronan (FS-HA)
Number of subjects: 60
Study 34933842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 36344917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + 1 µg/kg dexmedetomidine
Number of subjects: 60
Study 36344917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + 1 µg/kg fentanyl
Number of subjects: 60
Study 36344917 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine + normal saline
Number of subjects: 60
Study 36049647 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA-Li
Number of subjects: 42
Study 36049647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 34471960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 600 mg
Number of subjects: 24
Study 34471960 — intervention group
Group type: COMPARATOR
Intervention: Ipatasertib (fed state)
Number of subjects: 24
Study 34471960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib (dose range 200-800 mg)
Number of subjects: 24
Study 34791761 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial smartwatch with blood pressure-monitoring feature
Number of subjects: 60
Study 34791761 — intervention group
Group type: COMPARATOR
Intervention: Commercial smartwatch without blood pressure-monitoring feature
Number of subjects: 60
Study 33308134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sjogren's syndrome
Number of subjects: 216
Study 33308134 — intervention group
Group type: EXPERIMENTAL
Intervention: More than one diagnosis
Number of subjects: 216
Study 33308134 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis
Number of subjects: 216
Study 33308134 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients except those with PsA
Number of subjects: 216
Study 34984792 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg (OMA300)
Number of subjects: 418
Study 34984792 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 150 mg (OMA150)
Number of subjects: 418
Study 34984792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 34910825 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD+ABG+L-PRF
Number of subjects: 54
Study 34910825 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD+ABG
Number of subjects: 54
Study 34910825 — intervention group
Group type: COMPARATOR
Intervention: OFD
Number of subjects: 54
Study 33591279 — intervention group
Group type: EXPERIMENTAL
Intervention: Food4toddlers eHealth intervention (access to website for 6 months)
Number of subjects: 298
Study 33591279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 298
Study 33591279 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 298
Study 34217102 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention by telephone (BMI)
Number of subjects: 0
Study 36155370 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar diathermy
Number of subjects: 234
Study 36155370 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 234
Study 36155370 — intervention group
Group type: COMPARATOR
Intervention: Comparison of diathermy to scalpel
Number of subjects: 234
Study 32285996 — intervention group
Group type: EXPERIMENTAL
Intervention: UV lens replacement during blue-enriched light exposure
Number of subjects: 29
Study 32285996 — intervention group
Group type: EXPERIMENTAL
Intervention: BB lens replacement during blue-enriched light exposure
Number of subjects: 29
Study 32285996 — intervention group
Group type: COMPARATOR
Intervention: Non-cataract controls during blue-enriched light exposure
Number of subjects: 29
Study 35213484 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with propofol
Number of subjects: 0
Study 35213484 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 0
Study 33415743 — intervention group
Group type: EXPERIMENTAL
Intervention: CART algorithm for classifying severity of malnutrition
Number of subjects: 3998
Study 33415743 — intervention group
Group type: EXPERIMENTAL
Intervention: CART model performance in validation group
Number of subjects: 3998
Study 33415743 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of CART model
Number of subjects: 3998
Study 33660386 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Treatment as an Add-On Therapy
Number of subjects: 0
Study 33660386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35672726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination condition (30% price increase + information nudge)
Number of subjects: 533
Study 35672726 — intervention group
Group type: EXPERIMENTAL
Intervention: Price condition (30% price increase for meat)
Number of subjects: 533
Study 35672726 — intervention group
Group type: EXPERIMENTAL
Intervention: Information nudge condition (information about environmental impact of meat production)
Number of subjects: 533
Study 35672726 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 533
Study 36031405 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant-HA influenza vaccine (RIV) in 2 consecutive seasons
Number of subjects: 414
Study 36031405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell culture-based inactivated influenza vaccine (ccIIV) in 2 consecutive seasons
Number of subjects: 414
Study 36031405 — intervention group
Group type: EXPERIMENTAL
Intervention: RIV/ccIIV
Number of subjects: 414
Study 36031405 — intervention group
Group type: COMPARATOR
Intervention: IIV/IIV
Number of subjects: 414
Study 34014991 — intervention group
Group type: EXPERIMENTAL
Intervention: Good knowledge about diabetes
Number of subjects: 626
Study 34014991 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational status
Number of subjects: 626
Study 34014991 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 626
Study 34014991 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attitude towards diabetes
Number of subjects: 626
Study 33482949 — intervention group
Group type: EXPERIMENTAL
Intervention: Text reminders
Number of subjects: 4545
Study 33482949 — intervention group
Group type: COMPARATOR
Intervention: No preference for reminder type
Number of subjects: 4545
Study 36498690 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-Assisted Manual Therapy (IAMT)
Number of subjects: 67
Study 36498690 — intervention group
Group type: COMPARATOR
Intervention: Heat application (comparison group)
Number of subjects: 67
Study 36498690 — intervention group
Group type: COMPARATOR
Intervention: Pressure-less placebo (placebo group)
Number of subjects: 67
Study 32687762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate prehydration
Number of subjects: 0
Study 32687762 — intervention group
Group type: COMPARATOR
Intervention: No prehydration
Number of subjects: 0
Study 34435429 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOO-enriched chocolate spread
Number of subjects: 20
Study 34435429 — intervention group
Group type: COMPARATOR
Intervention: Palm oil-enriched chocolate spread
Number of subjects: 20
Study 32068582 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization in neurocritical care patients
Number of subjects: 0
Study 33617382 — intervention group
Group type: EXPERIMENTAL
Intervention: Total joint replacement (TJR) surgery
Number of subjects: 339
Study 33617382 — intervention group
Group type: EXPERIMENTAL
Intervention: Current therapy satisfaction
Number of subjects: 339
Study 34244006 — intervention group
Group type: COMPARATOR
Intervention: RV3 rotavirus vaccine (Bio Farma) in neonates
Number of subjects: 100
Study 34244006 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3 rotavirus vaccine (Bio Farma) in adults and children
Number of subjects: 100
Study 35177687 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 411
Study 35177687 — intervention group
Group type: EXPERIMENTAL
Intervention: % fat mass
Number of subjects: 411
Study 35177687 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass index
Number of subjects: 411
Study 35177687 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass index
Number of subjects: 411
Study 35177687 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater cardiorespiratory fitness
Number of subjects: 411
Study 35177687 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor fitness
Number of subjects: 411
Study 33600060 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 2 g/kg IVIG once
Number of subjects: 404
Study 33600060 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 1 g/kg IVIG for 2 consecutive days
Number of subjects: 404
Study 33600060 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 1 g/kg IVIG once
Number of subjects: 404
Study 33600060 — intervention group
Group type: COMPARATOR
Intervention: Control: Aspirin 30 mg/kg/d
Number of subjects: 404
Study 33600060 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 404
Study 32282467 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane plus standard of care (m-SoC) analgesia
Number of subjects: 351
Study 32282467 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care (p-SoC)
Number of subjects: 351
Study 36038131 — intervention group
Group type: EXPERIMENTAL
Intervention: RDS (Reliever Digihaler System)
Number of subjects: 333
Study 36038131 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 333
Study 34391961 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels assessed using the Baecke Questionnaire of Habitual Physical Activity
Number of subjects: 100
Study 34391961 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity indices (work index, sport index, leisure-time index, total activity index)
Number of subjects: 100
Study 33214515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation coach
Number of subjects: 200
Study 33214515 — intervention group
Group type: COMPARATOR
Intervention: Noncoach clinical provider
Number of subjects: 200
Study 32068688 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-814 50 mg
Number of subjects: 76
Study 32068688 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-814 100 mg
Number of subjects: 76
Study 32068688 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-814 150 mg
Number of subjects: 76
Study 32068688 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-814 300 mg
Number of subjects: 76
Study 32068688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 35135060 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct endovascular thrombectomy
Number of subjects: 780
Study 35135060 — intervention group
Group type: COMPARATOR
Intervention: Standard bridging IV thrombolysis followed by endovascular thrombectomy
Number of subjects: 780
Study 33513636 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral vaginal sacrospinous fixation with anterior mesh (VSF-AM group; n=20)
Number of subjects: 40
Study 33513636 — intervention group
Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy (ASC group; n=20)
Number of subjects: 40
Study 33513636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgeries (VSF-AM and ASC)
Number of subjects: 40
Study 35537640 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations with patients with AAA
Number of subjects: 342
Study 35537640 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations with patients with IC
Number of subjects: 342
Study 35537640 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations with patients with VV
Number of subjects: 342
Study 35537640 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations by a resident in training or nurse practitioner
Number of subjects: 342
Study 35537640 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations by a nurse practitioner
Number of subjects: 342
Study 35537640 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations longer than 30 minutes
Number of subjects: 342
Study 33612644 — intervention group
Group type: EXPERIMENTAL
Intervention: Catfish oil enriched with omega-3 (CO)
Number of subjects: 29
Study 33612644 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SO)
Number of subjects: 29
Study 33612644 — intervention group
Group type: COMPARATOR
Intervention: Commercial fish oil (CFO)
Number of subjects: 29
Study 34806658 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. lidocaine (1.5 mg/kg later 2 mg/kg/hour)
Number of subjects: 40
Study 34154439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (capsule-delivered)
Number of subjects: 102
Study 34154439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 32270927 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE)
Number of subjects: 20
Study 32270927 — intervention group
Group type: COMPARATOR
Intervention: Non-Time-Restricted Eating (non-TRE)
Number of subjects: 20
Study 34850043 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa triptorelin
Number of subjects: 281
Study 34850043 — intervention group
Group type: COMPARATOR
Intervention: Control arm (chemotherapy alone)
Number of subjects: 281
Study 32304151 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (≥10,000 steps on school holidays)
Number of subjects: 190
Study 32304151 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting screen time (<90 min on weekdays and <150 min on school holidays)
Number of subjects: 190
Study 32304151 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 190
Study 32304151 — intervention group
Group type: COMPARATOR
Intervention: Walking vs Control
Number of subjects: 190
Study 35170401 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted videos
Number of subjects: 1353
Study 35170401 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored videos
Number of subjects: 1353
Study 35170401 — intervention group
Group type: COMPARATOR
Intervention: Generic videos
Number of subjects: 1353
Study 34272817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin-enriched orange juice (EOJ)
Number of subjects: 159
Study 34272817 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (OJ)
Number of subjects: 159
Study 34272817 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 159
Study 36180564 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium cut-off membranes (MCO)
Number of subjects: 46
Study 36180564 — intervention group
Group type: COMPARATOR
Intervention: High flux-HD
Number of subjects: 46
Study 32976331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and visual education with photographs (in-person)
Number of subjects: 103
Study 32976331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and visual education with photographs (video)
Number of subjects: 103
Study 32976331 — intervention group
Group type: COMPARATOR
Intervention: Oral only education
Number of subjects: 103
Study 32660442 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs) and Controlled Clinical Trials (CCTs)
Number of subjects: 380
Study 35956364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence
Number of subjects: 138
Study 35956364 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to the Mediterranean diet
Number of subjects: 138
Study 33607831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided multiple nerve blocks (intercostal nerve blocks, interscalene brachial plexus, and supraclavicular nerve blocks) with local anesthesia (0.3% ropivacaine: 5 ml for each intercostal nerve block, 8 ml for brachial plexus block, 7 ml for supraclavicular nerve block) and basic sedation.
Number of subjects: 80
Study 33607831 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 80
Study 35669353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 12 mg (Iv12)
Number of subjects: 112
Study 35669353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 24 mg (Iv24)
Number of subjects: 112
Study 35669353 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 112
Study 35669353 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (Iv12, Iv24, Control)
Number of subjects: 112
Study 35669353 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate illness
Number of subjects: 112
Study 34538402 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring for one year (Arm A)
Number of subjects: 0
Study 34538402 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (PD-L1 inhibitor) 4-weekly for one year (Arm B)
Number of subjects: 0